Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tejas Patel

Showing results (1-10 of 188) with videos related to

Pageof 19
Sort By:
Annals of Internal Medicine|October 18, 2016
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 yTejas Patel
Annals of Internal Medicine|August 20, 2019
Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney diseaseTejas Patel
Annals of Internal Medicine|March 6, 2023
SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetesTejas Patel
Indian Heart Journal|November 29, 2008
Right trans-radial approach-working through arteria lusoriaTejas Patel
Indian Heart Journal|August 26, 2015
Government or private practice: Does it really matter in India?Surender Deora, Tejas Patel
Annals of Internal Medicine|January 17, 2018
Review: In adults, contrast-enhanced CT is not linked to acute kidney injury or mortality vs noncontrast CTTejas Patel, Vihas Patel
Heart Asia|June 22, 2016
Left atrium 'Egg shell calcification'Surender Deora, Tejas Patel
Cureus|April 6, 2026
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Conditions Beyond Heart Failure and Chronic Kidney Disease: Emerging Evidence, Mechanisms, and Practical ConsiderationsDigantkumar Patel, Tejas Patel
Annals of Internal Medicine|February 21, 2018
Review: DOACs reduce intracranial hemorrhage more than warfarin in AF with CKDTejas Patel, Vihas Patel
Seminars in Dialysis|March 10, 2010
Cardiovascular complications in diabetic kidney diseaseTejas Patel, David M Charytan
Pageof 19

Showing results (1-10 of 188) with videos related to

Sort By:
Pageof 19
Annals of Internal Medicine|October 18, 2016
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 yTejas Patel
Annals of Internal Medicine|August 20, 2019
Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney diseaseTejas Patel
Annals of Internal Medicine|March 6, 2023
SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetesTejas Patel
Indian Heart Journal|November 29, 2008
Right trans-radial approach-working through arteria lusoriaTejas Patel
Indian Heart Journal|August 26, 2015
Government or private practice: Does it really matter in India?Surender Deora, Tejas Patel
Annals of Internal Medicine|January 17, 2018
Review: In adults, contrast-enhanced CT is not linked to acute kidney injury or mortality vs noncontrast CTTejas Patel, Vihas Patel
Heart Asia|June 22, 2016
Left atrium 'Egg shell calcification'Surender Deora, Tejas Patel
Cureus|April 6, 2026
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Conditions Beyond Heart Failure and Chronic Kidney Disease: Emerging Evidence, Mechanisms, and Practical ConsiderationsDigantkumar Patel, Tejas Patel
Annals of Internal Medicine|February 21, 2018
Review: DOACs reduce intracranial hemorrhage more than warfarin in AF with CKDTejas Patel, Vihas Patel
Seminars in Dialysis|March 10, 2010
Cardiovascular complications in diabetic kidney diseaseTejas Patel, David M Charytan
Pageof 19